Absorbable iron-based instrument

By installing degradable polyester on the surface or inside of the iron-based instrument, the degradation process is adjusted, the corrosion unevenness of iron-based instruments is solved, the early corrosion uniformity is improved, and the biological safety risks and the risk of reducing the effectiveness of the instrument is reduced. .

CN119034017APending Publication Date: 2024-11-29BIOTYX MEDICAL (SHENZHEN) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410838692.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2016-12-30
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Uneven corrosion of iron-based implantable devices in the human body leads to early reduction of mechanical properties and biological safety risks, and accelerated corrosion of degradable polyesters may lead to local fractures and biological abnormalities.

Method used

By loading degradable polyester on the surface or inside of the iron-based instrument, adjusting its residual monomer content and mass fraction of the low molecular weight part, controlling the degradation process of the polyester to improve corrosion uniformity and reduce the early corrosion inhomogeneity caused by corrosion inequality. risk.

Benefits of technology

The corrosion uniformity of iron-based instruments in the early stage of implantation is achieved, which avoids the reduction in effectiveness and biological safety risks caused by rapid uneven corrosion, and reduces the potential harm to the human body.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119034017A_ABST
    Figure CN119034017A_ABST
Patent Text Reader

Abstract

The absorbable iron-based instrument disclosed by the invention comprises an iron-based matrix and degradable polyester in contact with the surface of the iron-based matrix. The mass fraction of the low-molecular-weight part of the degradable polyester is less than or equal to 5%, and the molecular weight of the low-molecular-weight part is less than 10,000; or the mass fraction of the residual monomer in the degradable polyester is less than or equal to 2%. By controlling the mass fraction of the low-molecular-weight part in the degradable polyester applied to the iron-based instrument or the mass fraction of the residual monomer in the degradable polyester, the corrosion of the absorbable iron-based instrument at the early stage of implantation is more uniform. Meanwhile, in the corrosion process of the absorbable iron-based instrument in the early stage of implantation, a large number of degradation products cannot be generated in a short time. Therefore, effectiveness reduction or biological safety risks caused by rapid and non-uniform corrosion of the iron-based instrument in the early stage of implantation can be effectively prevented.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to implantable medical devices, and in particular to absorbable iron-based devices. Background Art

[0002] Iron is an important element in the human body and is involved in many biochemical processes. Implantable devices made of pure iron or iron-based alloys can gradually corrode and be absorbed by the human body after being implanted. They are safer and more reliable, and can effectively avoid long-term adverse reactions caused by permanent implants remaining in the human body for a long time, such as long-term vascular restenosis, inflammatory reactions, and the inability to re-intervene at the implant site.

[0003] The corrosion rate of iron-based devices in the biological environment is relatively slow, and applying degradable polyester on their surface can accelerate the corrosion of iron-based devices. The principle of degradable polyester accelerating the corrosion of iron-based devices is that in the early stage of implantation of iron-based devices containing degradable polyester in the body, the soluble oligomers and residual monomers in the degradable polyester are released into the body environment, forming a local weak acidic environment around the iron-based matrix, thereby accelerating the local corrosion of the iron-based matrix and the degradation of the degradable polyester itself. In addition, the low molecular weight part of the degradable polyester will also degrade into soluble oligomers or monomers relatively quickly, further accelerating the local corrosion of the iron-based matrix and the degradation of the degradable polyester itself.

[0004] Due to the material composition, structure, size and stress environment of the iron-based matrix of iron-based instruments, the corrosion of iron-based instruments is characterized by unevenness. After the iron-based instrument is implanted in the patient's body, it will generally complete endothelialization within 1 month. Therefore, clinical requirements require that it can maintain a stable framework structure for at least 1 month after implantation and have good early mechanical properties. Slightly uneven corrosion of iron-based instruments usually does not lead to serious consequences such as local fracture of the instrument and collapse of the supporting structure within 1 month of implantation. However, the degradable polyester applied to the surface of the iron-based instrument will aggravate the uneven corrosion of the iron-based instrument, which may cause local fracture of the iron-based instrument in the early stage of implantation, affecting the mechanical properties of the iron-based instrument in the early stage of implantation. In addition, uneven corrosion will cause corrosion products to accumulate locally in the iron-based instrument, and human tissue in contact with this part may produce biological abnormalities and biological safety risks. Summary of the invention

[0005] Based on this, it is necessary to provide an absorbable iron-based device, which can improve the corrosion uniformity of the iron-based device in the early stage of implantation by carrying a degradable polyester on the surface or inside of the iron-based matrix, thereby reducing the reduced effectiveness and biological safety risks caused by the early uneven corrosion of the iron-based device.

[0006] The degradation process of degradable polyester polymers is related to the residual monomer content and molecular weight distribution in the degradable polyester. The present invention controls the degradation process of the degradable polyester by adjusting the residual monomer content in the degradable polyester or the content of the low molecular weight part in the degradable polyester, thereby improving the corrosion uniformity of the iron-based device in the early stage of implantation and reducing the reduced effectiveness and biological safety risks of the implantable device caused by the uneven corrosion of the iron-based device in the early stage.

[0007] The present invention provides an absorbable iron-based device, comprising an iron-based substrate and a degradable polyester in contact with the surface of the iron-based substrate. The mass fraction of the low molecular weight part in the degradable polyester is less than or equal to 5%, and the molecular weight of the low molecular weight part is less than 10,000; or the mass fraction of the residual monomer in the degradable polyester is less than or equal to 2%.

[0008] In one embodiment, the mass fraction of the residual monomers is less than or equal to 1%.

[0009] In one embodiment, the mass fraction of the residual monomer is less than or equal to 0.1%. Since the number of monomer molecules is much greater than the number of polymer molecules at the same unit mass, and the monomer is easier to ionize than the polymer to produce acidic hydrogen ions, the mass fraction of the residual monomer in the degradable polyester has a greater impact on the early degradation process of the degradable polyester. When the mass fraction of the residual monomer in the degradable polyester is less than or equal to 1%, the acidity around the iron-based device in the early stage of degradation can be effectively reduced, making the early corrosion of the iron-based device more uniform.

[0010] Whether the corrosion of the iron-based instrument is uniform is evaluated by the corrosion uniformity index. The detection method of the corrosion uniformity index is as follows: after the iron-based instrument is corroded, the effective support part of the iron-based instrument is evenly divided into i sections with equal axial lengths, i is a natural number greater than or equal to 3, and the effective support part refers to the part of the iron-based instrument that is in direct contact with human tissue after being implanted in the human body. The mass of the iron element in the corrosion product attached to the surface of each section of the iron-based instrument and the mass of the residual iron element in each section of the iron-based instrument are detected respectively, and the sum of the two is the initial mass of the iron element of the section of the iron-based instrument before corrosion. The ratio between the mass of the iron element in the corrosion product of each section of the iron-based instrument and the initial mass of the iron element of the section of the iron-based instrument before corrosion is calculated, for a total of i. The standard deviation between the i ratios is defined as the corrosion uniformity index of the iron-based instrument in the corrosion interval. When the corrosion uniformity index is ≤30%, the iron-based instrument is uniformly corroded in the corrosion interval; when the corrosion uniformity index is >30%, the iron-based instrument is unevenly corroded in the corrosion interval.

[0011] In one embodiment, the mass fraction of the low molecular weight part is less than or equal to 2%. Since the low molecular weight part in the degradable polyester is more easily degraded into soluble oligomers in the early stage of degradation, reducing the content of the low molecular weight part in the degradable polyester can effectively reduce the acidity around the iron-based device in the early stage of degradation.

[0012] In one embodiment, the molecular weight of the low molecular weight portion is less than 100,000.

[0013] In one embodiment, the degradable polyester is obtained by separating and / or purifying the raw material of the degradable polyester by precipitation method, gel permeation chromatography method, ultrafiltration membrane filtration method or extraction method.

[0014] In one embodiment, the ratio of the mass of the degradable polyester to the mass of the iron-based matrix is ​​in the range of 1:(1-200). The ratio of the mass of the degradable polyester to the mass of the iron-based matrix within this range can ensure that the iron-based device can be degraded quickly after implantation and will not remain in the human body for a long time, thereby reducing long-term safety risks.

[0015] In one of the embodiments, the ratio of the mass of the degradable polyester to the mass of the iron-based matrix is ​​in the range of 1:(6-100).

[0016] In one embodiment, the degradable polyester is selected from at least one of polylactic acid, polyglycolic acid, polybutylene succinate, polyhydroxyalkanoate, polycaprolactone, polyethylene adipate, polylactic acid-glycolic acid copolymer or polyhydroxybutyrate valerate copolymer. The degradable polyester is copolymerized or physically blended by at least two of the monomers constituting polylactic acid, polyglycolic acid, polybutylene succinate, polyhydroxyalkanoate, polycaprolactone, polyethylene adipate, polylactic acid-glycolic acid copolymer or polyhydroxybutyrate valerate copolymer.

[0017] In one embodiment, the degradable polyester is copolymerized or physically blended with at least one of the monomers constituting polylactic acid, polyglycolic acid, polybutylene succinate, polyhydroxyalkanoate, polycaprolactone, polyethylene adipate, polylactic acid-glycolic acid copolymer or polyhydroxybutyrate valerate copolymer and at least one of the monomers constituting polyanhydride, poly(malate), starch, chitosan, cellulose, polysaccharide or its derivatives.

[0018] In one embodiment, the degradable polyester is copolymerized or physically blended with at least one monomer constituting a degradable polymer and at least one monomer constituting a non-degradable polymer. The non-degradable part of the degradable polyester can reduce the acidic environment around the iron-based device and delay the early corrosion of the iron-based device.

[0019] In one embodiment, the non-degradable polymer includes polyurethane, polycarbonate, polymethyl methacrylate, polystyrene, polybutylene or polybutyl methacrylate.

[0020] The degradable polyester is in contact with the iron-based substrate in the form of a coating. The coating is in contact with the iron-based substrate in at least one of the following ways: the coating at least partially covers the surface of the iron-based substrate; or the iron-based substrate is provided with a gap or a groove, and the coating is provided in the gap or the groove; or the iron-based substrate has an inner cavity, and the coating is filled in the inner cavity.

[0021] In one embodiment, the thickness of the coating ranges from 2 to 100 micrometers. Further, the thickness of the coating ranges from 5 to 80 micrometers.

[0022] In one embodiment, the absorbable iron-based device further comprises an active drug mixed with the degradable polyester. The ratio of the mass of the degradable polyester to the mass of the active drug is in the range of (0.2-20):1.

[0023] In one embodiment, the active drug is selected from at least one of angiogenesis inhibitors, antiplatelet drugs, antithrombotic drugs, anti-inflammatory drugs or anti-allergic drugs. The angiogenesis inhibitor is selected from at least one of paclitaxel, paclitaxel derivatives, rapamycin or rapamycin derivatives. The antiplatelet drug is selected from cilostazol. The antithrombotic drug is selected from heparin. The anti-inflammatory drug is selected from dexamethasone. The anti-allergic drug is selected from at least one of diphenhydramine, chlorpheniramine, promethazine, hydrocortisone, triamcinolone acetonide, methylprednisolone, loratadine, fexofenadine, levocetirizine, mizolastine or ebastine.

[0024] In one embodiment, the iron-based device includes a vascular stent, a non-vascular intraluminal stent, an occluder, an orthopedic implant, a dental implant, a respiratory implant, a gynecological implant, an andrological implant, a suture or a bolt. The non-vascular intraluminal stent includes a tracheal stent, an esophageal stent, a urethral stent, an intestinal stent or a biliary stent. The orthopedic implant includes a fixing screw, a fixing rivet or a bone plate.

[0025] Compared with the prior art, the present invention has at least the following beneficial effects:

[0026] In the absorbable iron-based device of the present invention, a degradable polyester is arranged on the surface of the iron-based matrix. By controlling the residual monomer mass fraction of the degradable polyester applied to the surface of the iron-based matrix, or the mass fraction of the low molecular weight part of the degradable polyester, the corrosion of the absorbable iron-based device in the early stage of implantation is made more uniform. At the same time, during the corrosion process of the absorbable iron-based device in the early stage of implantation, a large amount of degradation products will not be generated in a short time. Therefore, it is possible to effectively prevent the reduction of the effectiveness of the implantable device or the biological safety risk caused by the rapid and uneven corrosion of the iron-based device in the early stage of implantation, thereby reducing the possibility of causing harm to the human body.

[0027] Figures and their descriptions

[0028] Figure 1a to Figure 1c This is a staining image of the pathological section of the tissue surrounding the stent when the stent of Example 1 was implanted into the abdominal aorta of a New Zealand rabbit for 3 days, wherein: Figure 1a This is a 25-fold magnified image of a pathological section stained under a microscope. Figure 1b This is a stained image of a pathological section under a microscope, magnified 100 times. Figure 1c This is a stained image of a pathological section magnified 200 times under a microscope;

[0029] Figure 2 This is a staining image of the pathological section of the tissue surrounding the stent when the stent of Example 2 was implanted into the abdominal aorta of a New Zealand rabbit for 7 days;

[0030] Figure 3a to Figure 3c This is a pathological section staining image of the tissue surrounding the stent when the stent of Comparative Example 1 was implanted into the abdominal aorta of a New Zealand rabbit for 3 days, wherein: Figure 3a This is a 25-fold magnified image of a pathological section stained under a microscope. Figure 3b This is a stained image of a pathological section magnified 100 times under a microscope. Figure 3c This is a stained image of a pathological section magnified 200 times under a microscope. DETAILED DESCRIPTION

[0031] First, the detection method of the degradable polyester and iron-based device related to the present invention is described as follows.

[0032] Method for testing the quality of degradable polyester

[0033] The mass of the degradable polyester is measured by the following method: weigh the total mass M0 of the iron-based device, remove the degradable polyester on the surface of the iron-based substrate with a good solvent for the degradable polyester, and then weigh the mass M of the iron-based substrate. 铁 The mass of the degradable polyester of the iron-based device is obtained by the difference method as (M0-M 铁 ).

[0034] Detection method of residual monomer mass fraction in degradable polyester

[0035] The mass fraction of residual monomers in degradable polyester = residual monomer mass M 单体 / Mass of degradable polyester (M0-M 铁 )×100%.

[0036] The mass of residual monomer M 单体 Detected by gas chromatography. The detection conditions are as follows:

[0037] Agilent 7820A gas chromatograph from Agilent, USA. Chromatographic column: CD-ACID WAX chromatographic column (size: 30m×0.32mm, 0.50 micron) from Shanghai Anpu. Column temperature and heating conditions: first increase the temperature from 50℃ to 180℃, heating rate 20℃ / min, keep warm for 5min; then increase the temperature from 180℃ to 200℃, heating rate 10℃ / min, keep warm for 6.5min. Injection chamber temperature: 200℃. Detector temperature: 250℃. Column flow rate: 1.8mL / min. Split ratio 2:1. Tail gas: 25mL / min. Hydrogen flow rate: 30mL / min. Air flow rate: 300mL / min.

[0038] Method for detecting weight average molecular weight, dispersion coefficient and molecular weight distribution of degradable polyester

[0039] The weight average molecular weight, dispersion coefficient and molecular weight distribution of the degradable polyester were tested using the GPC-multi-angle laser light scattering instrument combined with the molecular weight test system of Wyatt Company of the United States. The test system includes a liquid phase pump and injector of Agilent Company of the United States, an Agilent PL MIXED-C type GPC column (size: 7.5×300mm, 5 microns) of Agilent Company of the United States, a multi-angle laser light scattering instrument and a differential detector of Wyatt Company of the United States. The test conditions are: mobile phase: tetrahydrofuran; pump flow rate: 1mL / min; injection volume: 100μL; laser wavelength: 663.9nm; test temperature: 35℃.

[0040] Corrosion uniformity test method for iron-based equipment

[0041] The corrosion uniformity of iron-based devices is evaluated by the corrosion uniformity index. The corrosion uniformity index K can be detected by an in vitro test method, which specifically includes the following steps: Place the iron-based device in a sample bottle that can soak the iron-based device with the minimum volume, and add physiological saline to completely immerse the iron-based device. Place the sample bottle in a constant temperature water bath environment of 36.5°C to 37.5°C and oscillate at a rate of 40 to 80 rpm. Then at a predetermined observation time point, such as 3 days or 7 days, take out the iron-based device, and evenly divide the effective support part of the iron-based device into i segments of equal axial length, where i is a natural number greater than or equal to 3. The effective support part refers to the part of the iron-based device that is in direct contact with human tissue after being implanted in the human body. For example, for a vascular stent with a regular shape, its effective support part refers to the entire vascular stent; for a vascular filter, its effective support part refers to the middle section of the device used to support the blood vessel without the filter screens at both ends. Then, the i-stage iron-based device is placed in i parts of 3% tartaric acid solution for ultrasonic treatment, so that the corrosion products attached to the surface of the i-stage iron-based device fall off in the i parts of tartaric acid solution. After the ultrasonic treatment, the i-stage iron-based device is dried and weighed to obtain the mass m1, m2, m3…m of the i-stage iron-based device. i Then, the tartaric acid solution corresponding to the i-section iron-based device is dissolved in i portions of concentrated nitric acid, and digested in a microwave digestion instrument until i portions of mixed solution are obtained. At this time, the corrosion products are converted into a detectable dissolved state. Distilled water is added to the i portions of mixed solution to make the volume V1, V2, V3...V i , the concentrations of iron ions in the i-volume mixed solution were measured by atomic absorption spectroscopy, C1, C2, C3…C i According to M i =C i ×V i , calculate the mass M1, M2, M3…M of the iron element in the i-volume mixed solution after volume adjustment i , which is the mass of iron in the corrosion products produced by the i-th section of the iron-based device during the corrosion process. Therefore, the initial mass of iron in the i-th section of the iron-based device before corrosion is m i +M i , and then according to P i =M i / (m i +M i )×100%, and obtain the ratios of the mass of the iron element in the corrosion product of each section of the iron-based equipment after corrosion to the initial mass of the iron element in the section of the iron-based equipment before corrosion, P1, P2, P3…P i , a total of i. Then, P1, P2, P3…P iThe standard deviation between them is the corrosion uniformity index of the iron-based equipment in this corrosion interval. When the corrosion uniformity index is ≤30%, it is considered that the iron-based equipment is uniformly corroded in this corrosion interval; when the corrosion uniformity index is greater than 30%, it is considered that the iron-based equipment is non-uniformly corroded in this corrosion interval.

[0042] The detection conditions of atomic absorption spectrometry are: 240FS atomic absorption spectrometer from Agilent Technologies, USA; detection wavelength: 248.3 nm; slit: 0.2 nm; combustion-supporting gas: acetylene, combustion-supporting gas flow rate: 2.0 L / min.

[0043] The corrosion uniformity index K can also be detected by an animal implantation test. Specifically, the absorbable iron-based device is implanted into the animal body, and then at a predetermined observation time point, the corroded iron-based device is taken out, the effective supporting part of the iron-based device is evenly divided into i segments of equal axial length, and the corrosion uniformity index K is tested.

[0044] Biological safety risk assessment method for iron-based devices

[0045] Biological safety risk refers to abnormal phenomena such as inflammatory reaction, cytotoxicity, sensitization, thrombosis or hemolysis caused by implanted iron-based devices in biological tissues or organisms. Animal implantation tests are used to examine whether the corrosion products produced by the early corrosion of iron-based devices pose biological safety risks to the surrounding tissues of animals. Specifically, the following steps are included: implant the iron-based device into the tissues (e.g., coronary arteries, abdominal aorta, iliac arteries, inferior vena cava) of small mammals (e.g., rabbits, dogs, pigs). Then, at predetermined observation time points, such as 7 days and 28 days, remove the iron-based device and its surrounding tissues, observe the appearance and inner wall corrosion of the iron-based device, observe whether there is product accumulation, whether severe local corrosion occurs, and whether there are biological morphological abnormalities (e.g., inflammatory reaction, thrombosis, decay, etc.) in the surrounding tissues of the iron-based device.

[0046] It should also be noted that the degradable polyester used in the technical solution of the present invention may be a commercially available product that meets the requirements for the mass fraction of the low molecular weight part or the mass fraction of the residual monomer in the technical solution, or it may be a prepared sample obtained by technicians in this field by separating and / or purifying commercially available degradable polyester raw materials.

[0047] Separation and purification method of degradable polyester

[0048] In the present invention, the following four methods can be used to separate and / or purify the polyester raw material to obtain the degradable polyester used in Examples 1 to 11. However, the separation and / or purification method of the degradable polyester is not limited to the following methods. The degradable polyester obtained by separating and / or purifying the degradable polyester raw material by any method can be applied to the absorbable iron-based device of the present invention as long as the mass fraction of the low molecular weight part or residual monomer of the degradable polyester can meet the requirements of the technical solution of the present invention.

[0049] Precipitation method: specifically includes the following steps: dissolving the degradable polyester raw material in a good solvent for degradable polyester (such as ethyl acetate, tetrahydrofuran, acetone, dichloromethane, chloroform, etc.) to obtain a degradable polyester solution. Then, a poor solvent for degradable polyester (such as methanol, ethanol, isopropanol, water, etc.) is added to the degradable polyester solution as a precipitant and mixed evenly, and a precipitate appears in the degradable polyester solution. After standing, pour out the liquid in the degradable polyester solution and retain the precipitate. Repeat the precipitation of the precipitate 2 to 3 times using the same method, and the precipitate obtained at last is dried to obtain the degradable polyester used in the absorbable iron-based device of the present invention.

[0050] Gel permeation chromatography (GPC): specifically includes the following steps: dissolving the degradable polyester raw material in a good solvent for degradable polyester (e.g., ethyl acetate, tetrahydrofuran, acetone, dichloromethane, chloroform, etc.) to obtain a degradable polyester solution. The degradable polyester solution is injected into a GPC column (e.g., PL MIXED-C GPC preparation column of Agilent, USA) through a liquid phase injection pump, and the degradable polyester in the degradable polyester solution flows out in descending order of molecular weight after passing through the GPC column. The effluent is retained for a certain period of time, and after drying, the degradable polyester used in the absorbable iron-based device of the present invention can be obtained.

[0051] Ultrafiltration membrane filtration method: specifically includes the following steps: dissolving the degradable polyester raw material in a good solvent for polyester (such as ethyl acetate, tetrahydrofuran, acetone, dichloromethane, chloroform, etc.) to obtain a degradable polyester solution, pressurizing the degradable polyester solution and passing it through an ultrafiltration membrane. At this time, most of the residual monomers, low molecular weight parts and solvents in the degradable polyester can pass through the ultrafiltration membrane, while the high molecular weight parts and a small amount of residual monomers and low molecular weight parts are retained on the surface of the ultrafiltration membrane by the ultrafiltration membrane. After drying the filter residue retained on the surface of the ultrafiltration membrane, the degradable polyester used in the absorbable iron-based device of the present invention can be obtained.

[0052] Extraction method: specifically comprises the following steps: soaking the degradable polyester raw material in a poor solvent for degradable polyester (such as water, methanol, ethanol, isopropanol, etc.). After a certain period of time, the degradable polyester is taken out and dried to obtain the degradable polyester used in the absorbable iron-based device of the present invention.

[0053] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the technical solution of the present invention is further described in detail below through specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0054] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the specification are only for the purpose of describing specific embodiments and are not intended to limit the present invention.

[0055] Example 1

[0056] Polylactic acid was separated and purified by GPC method to obtain polylactic acid with a residual monomer mass fraction of 0.1%. Polylactic acid with a residual monomer mass fraction of 0.1% was dissolved in ethyl acetate and sprayed on the surface of an iron-based alloy vascular stent with a carbon content of 2.11wt%, to obtain the degradable polyester coated iron-based alloy vascular stent of Example 1. In the degradable polyester coated iron-based alloy vascular stent of this embodiment, the average thickness of the degradable polyester coating is 5 microns. The mass ratio of the degradable polyester to the iron-based matrix is ​​1:80.

[0057] Three identical stents were made using the same raw materials and methods, and one of the stents was randomly placed in a sample bottle, and physiological saline was added to completely immerse the stent. The sample bottle was placed in a constant temperature water bath environment of 36.5°C to 37.5°C, and oscillated at a rate of 40 to 80 rpm. Then, after 3 days, the stent was taken out. The corroded stent was evenly divided into three sections of equal axial length, and the ratio of the mass of iron in the corrosion product of each section of the stent to the initial mass of iron in the section before corrosion was determined according to the aforementioned method, for a total of 3 ratios, and the standard deviation between the 3 ratios was calculated, which was the corrosion uniformity index of the stent provided in this embodiment. It was determined that the corrosion uniformity index of the stent provided in Example 1 was 16.6% when it was immersed in physiological saline for 3 days.

[0058] The other two stents were implanted into the abdominal aorta of two New Zealand rabbits of the same weight, gender, and age. The stent and its surrounding vascular tissue were removed from one New Zealand rabbit at 3 days and 28 days after implantation. The stent with vascular tissue was cut open and flattened along the axial direction, and the appearance integrity of the stent was observed under a microscope. It was also observed whether there was severe local corrosion or a large amount of corrosion product accumulation on the surface or inner wall of the stent, and whether there was any abnormal biological morphology in the tissue surrounding the stent. The tissue surrounding the stent was pathologically analyzed 3 days after implantation, and the tissue section staining is shown in the figure. Figure 1a to Figure 1c shown.

[0059] The results showed that after 3 days of implantation, the stent provided in this embodiment showed no signs of fracture, and no serious local corrosion or accumulation of large amounts of corrosion products occurred on the surface and inner wall of the stent. Figure 1a to Figure 1c It can be seen that when the stent provided in this embodiment was implanted for 3 days, no abnormal biological morphology was found in the tissues around the stent. When implanted for 28 days, no support rod breakage occurred in the stent, no serious local corrosion occurred on the surface and inner wall of the stent, and no accumulation of a large amount of corrosion products occurred, and no abnormal biological morphology was found in the tissues around the stent.

[0060] Example 2

[0061] The polylactic acid was separated and purified by GPC method to obtain a preferred polylactic acid having a mass fraction of 2% of a low molecular weight portion with a molecular weight less than 100,000 and a mass fraction of 1.0% of residual monomers. The obtained preferred polylactic acid was dissolved in ethyl acetate and sprayed on the surface of a pure iron stent to obtain a degradable polyester coated pure iron stent of Example 2. In this embodiment, the average thickness of the degradable polyester coating was 5 microns. The mass ratio of the degradable polyester to the iron-based matrix was 1:100.

[0062] The degradable polyester-coated pure iron stent provided in Example 2 was implanted into the abdominal aorta of New Zealand rabbits. The stent and its surrounding vascular tissue were removed 7 days after implantation. The stent with vascular tissue was cut open and flattened along the axial direction, and the appearance integrity of the stent was observed under a microscope. It was also observed whether there was severe local corrosion on the surface or inner wall of the stent or a large amount of corrosion product accumulation, and whether there was abnormal biological morphology in the tissue surrounding the stent. The tissue surrounding the stent was pathologically analyzed, and the tissue section staining diagram was as shown in FIG. Figure 2 shown.

[0063] The results showed that after 7 days of implantation, the stent provided by this embodiment had no support rod fracture, and no serious local corrosion or accumulation of a large amount of corrosion products on the surface and inner wall of the stent. Figure 2 It can be seen that when the stent provided in this embodiment is implanted for 3 days, the tissue around the stent does not show abnormal biological morphology. According to the above-mentioned corrosion uniformity index determination method, the corrosion uniformity index of the stent provided in Example 2 when implanted for 7 days is 5.4%.

[0064] Example 3

[0065] The polylactic acid was separated and purified by ultrafiltration membrane filtration to obtain a preferred polylactic acid with a residual monomer mass fraction of 0.05%. The obtained preferred polylactic acid was dissolved in ethyl acetate and sprayed on the surface of the iron-based alloy stent to obtain the degradable polyester-coated iron-based alloy stent of Example 3. In this embodiment, the average thickness of the degradable polyester coating was 2 microns. The mass ratio of the degradable polyester to the iron-based matrix was 1:200.

[0066] The degradable polyester-coated iron-based alloy stent provided in Example 3 was implanted into the abdominal aorta of New Zealand rabbits. The stent and its surrounding vascular tissue were removed 7 days after implantation. The stent with vascular tissue was cut and flattened along the axial direction, and the appearance integrity of the stent was observed under a microscope, and whether there was severe local corrosion on the surface or inner wall of the stent or a large amount of corrosion product accumulation, and whether there was abnormal biological morphology in the tissue surrounding the stent was observed.

[0067] The results showed that when the stent provided in this embodiment was implanted for 7 days, there was no fracture of the support rods of the stent, no serious local corrosion and accumulation of a large amount of corrosion products on the surface and inner wall of the stent, and no abnormal biological morphology of the tissues surrounding the stent.

[0068] According to the aforementioned method for measuring the corrosion uniformity index, the corrosion uniformity index of the stent provided in Example 3 was measured to be 6.8% at 7 days after implantation.

[0069] Example 4

[0070] After dissolving the preferred polycaprolactone having a mass fraction of 5% of the low molecular weight portion with a molecular weight of less than 10,000 in ethyl acetate, the mixture was sprayed on the surface of the pure iron stent to obtain the degradable polyester coated pure iron stent of Example 4. In this embodiment, the average thickness of the degradable polyester coating was 2 microns. The mass ratio of the degradable polyester to the iron-based matrix was 1:200.

[0071] The degradable polyester-coated pure iron stent provided in Example 4 was implanted into the abdominal aorta of New Zealand rabbits. The stent and its surrounding vascular tissue were removed 7 days after implantation. The stent with vascular tissue was cut and flattened along the axial direction, and the appearance integrity of the stent was observed under a microscope, and whether there was severe local corrosion on the surface or inner wall of the stent or a large amount of corrosion product accumulation, and whether there was abnormal biological morphology in the tissue surrounding the stent was observed.

[0072] The results showed that when the stent provided in this embodiment was implanted for 7 days, there was no fracture of the support rods of the stent, no serious local corrosion and accumulation of a large amount of corrosion products on the surface and inner wall of the stent, and no abnormal biological morphology of the tissues surrounding the stent.

[0073] According to the aforementioned method for measuring the corrosion uniformity index, the corrosion uniformity index of the stent provided in Example 4 was measured to be 14.4% at 7 days after implantation.

[0074] Example 5

[0075] The polylactic acid is separated and purified by precipitation method to obtain a preferred polylactic acid having a residual monomer mass fraction of 0.1% and a low molecular weight fraction of 1.1% with a molecular weight of less than 100,000. The preferred polylactic acid is mixed with rapamycin in a mass ratio of 2:1 and dissolved in ethyl acetate, and then sprayed on the surface of the iron-based alloy stent to obtain the degradable polyester coated iron-based alloy stent of Example 5. In this embodiment, the average thickness of the degradable polyester coating is 80 microns. The mass ratio of the degradable polyester to the iron-based matrix is ​​1:3.

[0076] Two stents identical to the degradable polyester-coated iron-based alloy stent provided in Example 5 were made using the same raw materials and methods, and implanted into the abdominal aorta of two New Zealand rabbits of the same weight, gender, and age. The stent and its surrounding vascular tissue were taken out of one New Zealand rabbit at 7 days and 28 days after implantation. The stent with vascular tissue was cut and flattened along the axial direction, and the appearance integrity of the stent was observed under a microscope, and whether there was severe local corrosion on the surface or inner wall of the stent or a large amount of corrosion product accumulation, as well as whether there was abnormal biological morphology in the tissue surrounding the stent, were observed.

[0077] The results showed that when the stent provided in this embodiment was implanted for 7 days, there was no fracture of the support rods in the stent, no serious local corrosion and accumulation of a large number of corrosion products on the surface and inner wall of the stent, and no abnormal biological morphology in the tissues around the stent. When implanted for 28 days, there was no fracture of the support rods in the stent, no serious local corrosion and accumulation of a large number of corrosion products on the surface and inner wall of the stent, and no abnormal biological morphology in the tissues around the stent.

[0078] According to the aforementioned method for measuring the corrosion uniformity index, the corrosion uniformity index of the stent provided in Example 5 was measured at 7 days and 28 days after implantation. After measurement, the corrosion uniformity index of the stent provided in Example 5 was 7.7% at 7 days after implantation. The corrosion uniformity index of the stent provided in Example 5 was 16.1% at 28 days after implantation.

[0079] Example 6

[0080] The polylactic acid-glycolic acid copolymer is separated and purified by extraction to obtain a preferred polylactic acid-glycolic acid copolymer with a residual monomer mass fraction of 2%. The obtained preferred polylactic acid-glycolic acid copolymer is mixed with paclitaxel and dexamethasone in a mass ratio of 4:1:1 and dissolved in ethyl acetate, and then sprayed on the surface of the iron-based alloy stent to obtain the degradable polyester coated iron-based alloy stent of Example 6. In this embodiment, the average thickness of the degradable polyester coating is 10 microns. The mass ratio of the degradable polyester mass to the iron-based matrix is ​​1:30.

[0081] The degradable polyester-coated iron-based alloy stent provided in Example 6 was implanted into the abdominal aorta of New Zealand rabbits. The stent and its surrounding vascular tissue were removed 7 days after implantation. The stent with vascular tissue was cut and flattened along the axial direction, and the appearance integrity of the stent was observed under a microscope, and whether there was severe local corrosion on the surface or inner wall of the stent or a large amount of corrosion product accumulation, and whether there was abnormal biological morphology in the tissue surrounding the stent was observed.

[0082] The results showed that when the stent provided in this embodiment was implanted for 7 days, there was no fracture of the support rods of the stent, no serious local corrosion and accumulation of a large amount of corrosion products on the surface and inner wall of the stent, and no abnormal biological morphology of the tissues surrounding the stent.

[0083] According to the aforementioned method for measuring the corrosion uniformity index, the corrosion uniformity index of the stent provided in Example 6 was measured to be 5.4% at 7 days after implantation.

[0084] Example 7

[0085] The polylactic acid is separated and purified by ultrafiltration membrane filtration to obtain a preferred polylactic acid having a mass fraction of 3.5% of a low molecular weight portion with a molecular weight of less than 100,000. The obtained preferred polylactic acid is blended with chitosan in a mass ratio of 1:1, mixed with heparin and cilostazol in a mass ratio of 8:1:1 and dissolved in ethyl acetate, and then sprayed on the surface of the iron-based alloy stent to obtain the degradable polyester coated iron-based alloy stent of Example 7. In this embodiment, the average thickness of the degradable polyester coating is 4 microns. The mass ratio of the degradable polyester mass to the iron-based matrix is ​​1:100.

[0086] The degradable polyester-coated iron-based alloy stent provided in Example 7 was implanted into the abdominal aorta of New Zealand rabbits. The stent and its surrounding vascular tissue were removed 7 days after implantation. The stent with vascular tissue was cut and flattened along the axial direction, and the appearance integrity of the stent was observed under a microscope, and whether there was severe local corrosion on the surface or inner wall of the stent or a large amount of corrosion product accumulation, and whether there was abnormal biological morphology in the tissue surrounding the stent was observed.

[0087] The results showed that when the stent provided in this embodiment was implanted for 7 days, there was no fracture of the support rods of the stent, no serious local corrosion and accumulation of a large amount of corrosion products on the surface and inner wall of the stent, and no abnormal biological morphology of the tissues surrounding the stent.

[0088] According to the aforementioned method for measuring the corrosion uniformity index, the corrosion uniformity index of the stent provided in Example 7 after implantation for 7 days was measured to be 3.9%.

[0089] Example 8

[0090] The polyglycolic acid was separated and purified by GPC to obtain a preferred polyglycolic acid with a residual monomer mass fraction of 2%. The obtained preferred polyglycolic acid was mixed with loratadine at a mass ratio of 0.2:1 and dissolved in acetone, and then sprayed on the surface of an iron-based alloy stent with a carbon content of 0.5%, to obtain a degradable polyester-coated iron-based alloy stent of Example 8. In this embodiment, the average thickness of the degradable polyester coating was 12 microns. The mass ratio of the degradable polyester mass to the iron-based substrate was 1:20.

[0091] The degradable polyester-coated iron-based alloy stent provided in Example 8 was implanted into the abdominal aorta of New Zealand rabbits. The stent and its surrounding vascular tissue were removed 7 days after implantation. The stent with vascular tissue was cut and flattened along the axial direction, and the appearance integrity of the stent was observed under a microscope, and whether there was severe local corrosion on the surface or inner wall of the stent or a large amount of corrosion product accumulation, and whether there was abnormal biological morphology in the tissue surrounding the stent was observed.

[0092] The results showed that when the stent provided in this embodiment was implanted for 7 days, there was no fracture of the support rods of the stent, no serious local corrosion and accumulation of a large amount of corrosion products on the surface and inner wall of the stent, and no abnormal biological morphology of the tissues surrounding the stent.

[0093] According to the aforementioned method for measuring the corrosion uniformity index, the corrosion uniformity index of the stent provided in Example 8 was measured to be 9.9% at 7 days after implantation.

[0094] Example 9

[0095] Commercially available polycaprolactone and polycarbonate were blended at a mass ratio of 2:1 to obtain a blend, and the mass fraction of the low molecular weight portion with a molecular weight of less than 10,000 in the blend was measured to be 2%. The blend was mixed with hydrocortisone at a mass ratio of 20:1 and dissolved in ethyl acetate, and then sprayed on the surface of the iron-based alloy stent to obtain the degradable polyester coated iron-based alloy stent of Example 9. In this embodiment, the average thickness of the degradable polyester coating was 8 microns. The mass ratio of the degradable polyester mass to the iron-based matrix was 1:30.

[0096] The degradable polyester-coated iron-based alloy stent provided in Example 9 was implanted into the abdominal aorta of New Zealand rabbits. The stent and its surrounding vascular tissue were removed 7 days after implantation. The stent with vascular tissue was cut and flattened along the axial direction, and the appearance integrity of the stent was observed under a microscope, and whether there was severe local corrosion on the surface or inner wall of the stent or a large amount of corrosion product accumulation, and whether there was abnormal biological morphology in the tissue surrounding the stent was observed.

[0097] The results showed that when the stent provided in this embodiment was implanted for 7 days, there was no fracture of the support rods of the stent, no serious local corrosion and accumulation of a large amount of corrosion products on the surface and inner wall of the stent, and no abnormal biological morphology of the tissues surrounding the stent.

[0098] According to the aforementioned method for measuring the corrosion uniformity index, the corrosion uniformity index of the stent provided in Example 9 after implantation for 7 days was measured to be 8.1%.

[0099] Example 10

[0100] The polyracemic lactic acid was separated and purified by GPC to obtain a preferred polyracemic lactic acid having a mass fraction of 0.5% of a low molecular weight portion with a molecular weight of less than 100,000 and a mass fraction of 1.5% of residual monomers. The obtained preferred polyracemic lactic acid was mixed with rapamycin in a mass ratio of 9:1 and dissolved in ethyl acetate, and then sprayed on the surface of the iron-based alloy stent to obtain the degradable polyester-coated iron-based alloy stent of Example 10. In this embodiment, the average thickness of the degradable polyester coating is 100 microns. The mass ratio of the degradable polyester mass to the iron-based matrix is ​​1:1.

[0101] The degradable polyester-coated iron-based alloy stent provided in Example 10 was implanted into the abdominal aorta of New Zealand rabbits. The stent and its surrounding vascular tissue were removed 7 days after implantation. The stent with vascular tissue was cut and flattened along the axial direction, and the appearance integrity of the stent was observed under a microscope, and whether there was severe local corrosion on the surface or inner wall of the stent or a large amount of corrosion product accumulation, and whether there was abnormal biological morphology in the tissue surrounding the stent was observed.

[0102] The results showed that when the stent provided in this embodiment was implanted for 7 days, there was no fracture of the support rods of the stent, no serious local corrosion and accumulation of a large amount of corrosion products on the surface and inner wall of the stent, and no abnormal biological morphology of the tissues surrounding the stent.

[0103] According to the aforementioned method for measuring the corrosion uniformity index, the corrosion uniformity index of the stent provided in Example 10 was measured to be 17.1% at 7 days after implantation.

[0104] Embodiment 11

[0105] The polybutylene succinate was separated and purified by precipitation method to obtain a preferred polybutylene succinate having a mass fraction of 2% of a low molecular weight portion with a molecular weight less than 100,000 and a mass fraction of 0.5% of residual monomers. The obtained preferred polybutylene succinate was mixed with isoprofen at a mass ratio of 4:1 and dissolved in ethyl acetate, and then sprayed on the surface of the iron-based alloy stent to obtain the degradable polyester-coated iron-based alloy stent of Example 11. In this embodiment, the average thickness of the degradable polyester coating is 40 microns. The mass ratio of the degradable polyester to the iron-based matrix is ​​1:6.

[0106] The degradable polyester-coated iron-based alloy stent provided in Example 11 was implanted into the abdominal aorta of New Zealand rabbits. The stent and its surrounding vascular tissue were removed 7 days after implantation. The stent with vascular tissue was cut and flattened along the axial direction, and the appearance integrity of the stent was observed under a microscope, and whether there was severe local corrosion on the surface or inner wall of the stent or a large amount of corrosion product accumulation, and whether there was abnormal biological morphology in the tissue surrounding the stent was observed.

[0107] The results showed that when the stent provided in this embodiment was implanted for 7 days, there was no fracture of the support rods of the stent, no serious local corrosion and accumulation of a large amount of corrosion products on the surface and inner wall of the stent, and no abnormal biological morphology of the tissues surrounding the stent.

[0108] According to the aforementioned method for measuring the corrosion uniformity index, the corrosion uniformity index of the stent provided in Example 11 after implantation for 7 days was measured to be 28.8%.

[0109] Comparative Example 1

[0110] After dissolving polylactic acid having a residual monomer content of 2.2% and a mass fraction of a low molecular weight portion of less than 10,000 of 10.9% in ethyl acetate, the polylactic acid was sprayed on the surface of an iron-based alloy vascular stent having a carbon content of 2.11wt%, thereby obtaining a degradable polyester-coated iron-based alloy vascular stent of Comparative Example 1. In the degradable polyester-coated iron-based alloy vascular stent of Comparative Example 1, the average thickness of the degradable polyester coating was 5 microns. The mass ratio of the degradable polyester to the iron-based matrix was 1:80.

[0111] Two stents identical to the biodegradable polyester-coated iron-based alloy vascular stent of Comparative Example 1 were made using the same raw materials and methods, and implanted into the abdominal aorta of two New Zealand rabbits of the same weight, gender, and age. The stent and its surrounding vascular tissue were taken out of a New Zealand rabbit at 3 days and 28 days after implantation, respectively. The stent with vascular tissue was cut open and flattened axially, and the appearance integrity of the stent was observed under a microscope. It was also observed whether there was severe local corrosion or a large amount of corrosion product accumulation on the surface or inner wall of the stent, as well as whether there were abnormal biological morphology in the tissue surrounding the stent. A histopathological analysis was performed on the tissue surrounding the stent 3 days after the stent was implanted, and the pathological section staining image is shown below. Figure 3a to Figure 3c shown.

[0112] The results showed that when the stent of comparative example 1 was implanted for 3 days, serious local corrosion occurred on the inner wall of the stent, and a large amount of corrosion products accumulated in the area where the local corrosion of the inner wall of the stent was serious. Figure 3a to Figure 3c It can be seen that thrombi appeared in the tissues around the stent. When the stent of comparative example 1 was implanted for 28 days, serious local corrosion occurred on the surface and inner wall of the stent, and some support rods broke, seriously affecting the overall support force of the stent. In addition, a large amount of corrosion products accumulated in the areas where the inner wall and surface of the stent were severely corroded locally, and multiple thrombi appeared in the surrounding tissues of the stent.

[0113] According to the aforementioned method for determining the corrosion uniformity index, the corrosion uniformity index of the stent of Comparative Example 1 was tested at 3 days and 28 days after implantation. After testing, the corrosion uniformity index of the stent of Comparative Example 1 was 32.3% at 3 days after implantation. The corrosion uniformity index of the stent of Comparative Example 1 was 33.6% at 28 days after implantation.

[0114] Compared with the stent provided in Example 2, the stent of Comparative Example 1 has a higher mass fraction of residual monomers of the degradable polyester applied on the surface of the stent, and a higher mass fraction of the low molecular weight part, which causes the degradable polyester to corrode rapidly and massively in the early stage of implantation, causing the stent matrix to corrode rapidly and unevenly in the early stage of implantation, and generating a large amount of corrosion products in a short period of time, resulting in reduced effectiveness of the stent and the generation of biological safety risks such as thrombosis.

[0115] In summary, in the absorbable iron-based device of the present invention, a degradable polyester is arranged on the surface of the iron-based matrix. By controlling the mass fraction of residual monomers in the degradable polyester applied on the surface of the iron-based matrix, or the mass fraction of the low molecular weight part of the degradable polyester, the early corrosion of the absorbable iron-based device provided by the present invention can be made more uniform. At the same time, during the corrosion process of the absorbable iron-based device in the early stage of implantation, a large amount of corrosion products will not be generated in a short time. Therefore, the absorbable iron-based device provided by the present invention can effectively prevent the reduction in effectiveness or biological safety risks caused by the rapid and uneven corrosion of the iron-based device in the early stage of implantation, thereby reducing the possibility of harm to the human body.

[0116] It should be noted that in Examples 1 to 11, only the absorbable iron-based device formed by coating the entire surface of the iron-based substrate with degradable polyester is schematically illustrated for the specific implementation of the present invention. It is understandable that the degradable polyester can also partially cover the surface of the iron-based substrate. It is understandable that when the iron-based substrate is provided with a gap or a groove, the degradable polyester can be provided in the gap or the groove. It is also understandable that when the iron-based substrate has an inner cavity, the degradable polyester can also be filled in the inner cavity.

[0117] It should also be noted that in Examples 1 to 11, only vascular stents are used to schematically illustrate the specific implementation of the present invention. The technical solution provided by the present invention can also be used for other implantable devices, such as other luminal stents (such as tracheal stents, esophageal stents, urethral stents, intestinal stents or biliary stents), other cardiovascular implants (such as heart occluders, vascular filters, vascular plugs), orthopedic implants (such as fixing screws, fixing rivets or bone plates), gynecological implants, andrological implants, respiratory implants, dental implants, sutures or bolts.

[0118] The embodiments of the present invention are described above, but the present invention is not limited to the above-mentioned specific implementation modes. The above-mentioned specific implementation modes are merely illustrative and not restrictive. Under the guidance of the present invention, ordinary technicians in this field can also make many forms without departing from the scope of protection of the purpose of the present invention and the claims, which are all within the protection of the present invention.

Claims

1. An absorbable iron-based device, comprising an iron-based substrate and a degradable polyester in contact with the surface of the iron-based substrate, characterized in that: The mass fraction of the low molecular weight part in the degradable polyester is less than or equal to 5%, and the molecular weight of the low molecular weight part is less than 10,000; or the mass fraction of the residual monomer in the degradable polyester is less than or equal to 2%.

2. The absorbable iron-based device according to claim 1, characterized in that The mass fraction of the residual monomers is less than or equal to 1%.

3. The absorbable iron-based device according to claim 1, characterized in that The mass fraction of the residual monomers is less than or equal to 0.1%.

4. The absorbable iron-based device according to claim 1, characterized in that The mass fraction of the low molecular weight part is less than or equal to 2%.

5. The absorbable iron-based device according to claim 1 or 4, characterized in that: The molecular weight of the low molecular weight portion is less than 100,000.

6. The absorbable iron-based device according to claim 1, characterized in that The degradable polyester is obtained by separating and / or purifying the raw material of the degradable polyester through a precipitation method, a gel permeation chromatography method, an ultrafiltration membrane filtration method or an extraction method.

7. The absorbable iron-based device according to claim 1, characterized in that The ratio of the mass of the degradable polyester to the mass of the iron-based matrix is ​​in the range of 1:(1-200).

8. The absorbable iron-based device according to claim 1, characterized in that The ratio of the mass of the degradable polyester to the mass of the iron-based matrix is ​​in the range of 1:(6-100).

9. The absorbable iron-based device according to claim 1, characterized in that The degradable polyester is selected from at least one of polylactic acid, polyglycolic acid, polybutylene succinate, polyhydroxyalkanoate, polycaprolactone, polyethylene adipate, polylactic acid-glycolic acid copolymer or polyhydroxybutyrate valerate copolymer, and the degradable polyester is copolymerized or physically blended by at least two of the monomers constituting polylactic acid, polyglycolic acid, polybutylene succinate, polyhydroxyalkanoate, polycaprolactone, polyethylene adipate, polylactic acid-glycolic acid copolymer or polyhydroxybutyrate valerate copolymer.

10. The absorbable iron-based device according to claim 1, characterized in that The degradable polyester is copolymerized or physically blended with at least one of the monomers constituting polylactic acid, polyglycolic acid, polybutylene succinate, polyhydroxyalkanoate, polycaprolactone, polyethylene adipate, polylactic acid-glycolic acid copolymer or polyhydroxybutyrate valerate copolymer and at least one of the monomers constituting polyanhydride, poly(malate), starch, chitosan, cellulose, polysaccharide or its derivatives.

11. The absorbable iron-based device according to claim 1, characterized in that The degradable polyester is formed by copolymerization or physical blending of at least one monomer constituting a degradable polymer and at least one monomer constituting a non-degradable polymer.

12. The absorbable iron-based device according to claim 11, characterized in that The non-degradable polymer includes polyurethane, polycarbonate, polymethyl methacrylate, polystyrene, polybutylene or polybutyl methacrylate.

13. The absorbable iron-based device according to claim 1, characterized in that The degradable polyester is in contact with the iron-based substrate in the form of a coating, and the coating is in contact with the iron-based substrate in at least one of the following ways: the coating at least partially covers the surface of the iron-based substrate; or the iron-based substrate is provided with a gap or a groove, and the coating is provided in the gap or the groove; or the iron-based substrate has an inner cavity, and the coating is filled in the inner cavity.

14. The absorbable iron-based device according to claim 13, characterized in that The thickness of the coating ranges from 2 to 100 micrometers, and further, the thickness of the coating ranges from 5 to 80 micrometers.

15. The absorbable iron-based device according to claim 1, characterized in that The absorbable iron-based device also includes an active drug mixed with the degradable polyester, and the ratio of the mass of the degradable polyester to the mass of the active drug is in the range of (0.2-20):

1.

16. The absorbable iron-based device according to claim 15, characterized in that The active drug is selected from at least one of angiogenesis inhibitors, antiplatelet drugs, antithrombotic drugs, anti-inflammatory drugs or anti-allergic drugs; the angiogenesis inhibitors are selected from at least one of paclitaxel, paclitaxel derivatives, rapamycin or rapamycin derivatives; the antiplatelet drugs are selected from cilostazol; the antithrombotic drugs are selected from heparin; the anti-inflammatory drugs are selected from dexamethasone; the anti-allergic drugs are selected from at least one of diphenhydramine, chlorpheniramine, promethazine, hydrocortisone, triamcinolone acetonide, methylprednisolone, loratadine, fexofenadine, levocetirizine, mizolastine or ebastine.

17. The absorbable iron-based device according to claim 1, characterized in that The iron-based devices include vascular stents, non-vascular intraluminal stents, occluders, orthopedic implants, dental implants, respiratory implants, gynecological implants, andrological implants, sutures or bolts; the non-vascular intraluminal stents include tracheal stents, esophageal stents, urethral stents, intestinal stents or biliary stents; the orthopedic implants include fixing screws, fixing rivets or bone plates.